Protocol summary
-
Study aim
-
The effect of yogurt fortified with probiotics, vitamin D and vitamin E on anthropometric indices, biochemical indices, blood pressure, sleep quality and mental health in patients with polycystic ovary syndrome.
-
Design
-
This clinical trial is randomized, double-blind, placebo-controlled and parallel in phase 3, on 90 eligible people. Ninety people are allocated between two groups by block randomization method (45 people in each group).
-
Settings and conduct
-
Patients referred to Shiraz Mother and Child Hospital after knowing about the study, if they agree and obtain written and informed consent, are randomly assigned to 2 study groups (using the block randomization method). The participants receive the yogurts corresponding to their group, which are named in line with the names of the groups with letters A and B for the blinding of the participant and the researcher, and consume them daily before meals for 8 weeks. Evaluation of anthropometric and biochemical indicators, and completion of mental health and sleep quality questionnaires are done before and after the study.
-
Participants/Inclusion and exclusion criteria
-
Exclusion criteria: Women with polycystic ovary syndrome between the ages of 18 and 45 who are not breastfeeding or pregnant.
Inclusion criteria: have no history of chronic diseases and have not taken antibiotics and nutritional supplements for 3 months before entering the study.
-
Intervention groups
-
1- Intervention group: 8 weeks of intaking120 grams per day of low-fat yogurt containing vitamin D (with a dose of 1000 IU or 25 micrograms), vitamin E (with a dose of 50 IU or 34 mg) and probiotics (Bifidobacterium animalis BB12 and Lactobacillus Acidophilus LA-5 in a dose of at least 10^6 CFU/gr)
2- Placebo group: 8 weeks of intaking120 grams per day of plain low-fat yogurt as a placebo
-
Main outcome variables
-
HOMA-IR
General information
-
Reason for update
-
-
Acronym
-
-
IRCT registration information
-
IRCT registration number:
IRCT20231210060323N1
Registration date:
2023-12-14, 1402/09/23
Registration timing:
prospective
Last update:
2023-12-19, 1402/09/28
Update count:
1
-
Registration date
-
2023-12-14, 1402/09/23
-
Registrant information
-
-
Recruitment status
-
Recruitment complete
-
Funding source
-
-
Expected recruitment start date
-
2024-01-21, 1402/11/01
-
Expected recruitment end date
-
2024-07-20, 1403/04/30
-
Actual recruitment start date
-
empty
-
Actual recruitment end date
-
empty
-
Trial completion date
-
empty
-
Scientific title
-
The Effect of Yoghurt Fortified with Probiotics and Vitamins D and E on Anthropometric and Biochemical Indices, Blood Pressure, Sleep Quality, and Mental Health in Patients with Polycystic Ovary Syndrome: A Randomized, Double-Blind, Controlled Clinical Trial
-
Public title
-
Effect of Yoghurt Fortified with Probiotics and Vitamins D and E in Treatment of Polycystic Ovary Syndrome
-
Purpose
-
Treatment
-
Inclusion/Exclusion criteria
-
Inclusion criteria:
Willingness to cooperate in the study and provide written consent
Being in the reproductive age range of 18-45 years
Diagnosis of polycystic ovary syndrome based on the Rotterdam criteria
No intake of alcohol or drugs
Not pregnant or breastfeeding
No menopause
No participate in other research studies
Exclusion criteria:
Using drugs affecting blood pressure, blood lipids, ovarian function, insulin sensitivity (including metformin, incretin, and Thiazolidinediones) and oral contraceptives (including progesterone and estrogen) since 3 months before entering the study.
Taking any nutritional supplements for 3 months before entering the study
Taking drugs affecting vitamin D metabolism
having diabetes, thyroid disease or any systemic disease (such as kidney, liver, digestive system, cardiovascular system)
Having disorders that lead to an increase in androgens in the blood (such as Cushing's syndrome, hyperprolactinemia)
-
Age
-
From 18 years old to 45 years old
-
Gender
-
Female
-
Phase
-
3
-
Groups that have been masked
-
-
Sample size
-
Target sample size:
90
-
Randomization (investigator's opinion)
-
Randomized
-
Randomization description
-
Participants will be randomly assigned using random blocks (ratio 1:1) for two groups (a control group and an intervention group). In this way, the double blocks will be created by someone outside the study. Then, a block is randomly selected to determine the assigned groups for the first two participants. In order to blind the researchers of this project, the assigned group will be placed in sealed envelopes by a person other than the researcher and a person outside the study, and in this way the allocation will be concealed. During the study, as each participant enters the study, according to the order, an envelope is opened and the assigned group is determined.
-
Blinding (investigator's opinion)
-
Double blinded
-
Blinding description
-
In order to blind the interventions, fortified yogurts (including two types of intervention yogurt and low-fat conventional yogurt) will be provided to people in deposable containers with the same color, smell, taste and appearance, which will be named with the letters A and B. The process of filling the yogurt containers and naming them will be done by someone outside the study, and the members of the research team and the participants of the different groups will be unaware of the type of intervention and the type of yogurt they received, so that the principles for blinding will be accomplished.
-
Placebo
-
Used
-
Assignment
-
Parallel
-
Other design features
-
Ethics committees
1
-
Ethics committee
-
-
Approval date
-
2023-10-22, 1402/07/30
-
Ethics committee reference number
-
IR.SUMS.SCHEANUT.REC.1402.104
Health conditions studied
1
-
Description of health condition studied
-
Polycystic ovary syndrome
-
ICD-10 code
-
E28.2
-
ICD-10 code description
-
Polycystic ovarian syndrome
Primary outcomes
1
-
Description
-
Homeostasis model assessment of insulin resistance
-
Timepoint
-
At the beginning of the study (before the start of the intervention) and at the end of the study (8 weeks after the start of the intervention)
-
Method of measurement
-
Formula
Secondary outcomes
1
-
Description
-
Weight
-
Timepoint
-
At the beginning of the study (before the start of the intervention) and at the end of the study (8 weeks after the start of the intervention)
-
Method of measurement
-
Scale
2
-
Description
-
Body Mass Index
-
Timepoint
-
At the beginning of the study (before the start of the intervention) and at the end of the study (8 weeks after the start of the intervention)
-
Method of measurement
-
Formula
3
-
Description
-
Waist Circumference
-
Timepoint
-
At the beginning of the study (before the start of the intervention) and at the end of the study (8 weeks after the start of the intervention)
-
Method of measurement
-
Stadiometer
4
-
Description
-
Hip Circumference
-
Timepoint
-
At the beginning of the study (before the start of the intervention) and at the end of the study (8 weeks after the start of the intervention)
-
Method of measurement
-
Stadiometer
5
-
Description
-
Waist to Hip Ratio
-
Timepoint
-
At the beginning of the study (before the start of the intervention) and at the end of the study (8 weeks after the start of the intervention)
-
Method of measurement
-
Formula
6
-
Description
-
Systolic Blood Pressure
-
Timepoint
-
At the beginning of the study (before the start of the intervention) and at the end of the study (8 weeks after the start of the intervention)
-
Method of measurement
-
Electronic Sphygmomanometer
7
-
Description
-
Diastolic Blood Pressure
-
Timepoint
-
At the beginning of the study (before the start of the intervention) and at the end of the study (8 weeks after the start of the intervention)
-
Method of measurement
-
Electronic Sphygmomanometer
8
-
Description
-
Fasting Blood Sugar
-
Timepoint
-
At the beginning of the study (before the start of the intervention) and at the end of the study (8 weeks after the start of the intervention)
-
Method of measurement
-
Pars Azmoon Kit
9
-
Description
-
Fasting Insulin
-
Timepoint
-
At the beginning of the study (before the start of the intervention) and at the end of the study (8 weeks after the start of the intervention)
-
Method of measurement
-
ELISA Kit
10
-
Description
-
The Quantitative Insulin Sensitivity Check Index
-
Timepoint
-
At the beginning of the study (before the start of the intervention) and at the end of the study (8 weeks after the start of the intervention)
-
Method of measurement
-
Formula
11
-
Description
-
Total Cholesterol
-
Timepoint
-
At the beginning of the study (before the start of the intervention) and at the end of the study (8 weeks after the start of the intervention)
-
Method of measurement
-
Pars Azmoon Kit
12
-
Description
-
Triglyceride
-
Timepoint
-
At the beginning of the study (before the start of the intervention) and at the end of the study (8 weeks after the start of the intervention)
-
Method of measurement
-
Pars Azmoon Kit
13
-
Description
-
Low-Density Lipoprotein Cholesterol
-
Timepoint
-
At the beginning of the study (before the start of the intervention) and at the end of the study (8 weeks after the start of the intervention)
-
Method of measurement
-
Pars Azmoon Kit
14
-
Description
-
High-Density Lipoprotein Cholesterol
-
Timepoint
-
At the beginning of the study (before the start of the intervention) and at the end of the study (8 weeks after the start of the intervention)
-
Method of measurement
-
Pars Azmoon Kit
15
-
Description
-
Total Testosterone
-
Timepoint
-
At the beginning of the study (before the start of the intervention) and at the end of the study (8 weeks after the start of the intervention)
-
Method of measurement
-
ELISA Kit
16
-
Description
-
Sex Hormone Binding Globulin
-
Timepoint
-
At the beginning of the study (before the start of the intervention) and at the end of the study (8 weeks after the start of the intervention)
-
Method of measurement
-
ELISA Kit
17
-
Description
-
Dehydroepiandrosterone Sulfate
-
Timepoint
-
At the beginning of the study (before the start of the intervention) and at the end of the study (8 weeks after the start of the intervention)
-
Method of measurement
-
ELISA Kit
18
-
Description
-
Luteinizing Hormone
-
Timepoint
-
At the beginning of the study (before the start of the intervention) and at the end of the study (8 weeks after the start of the intervention)
-
Method of measurement
-
Pars Azmoon Kit
19
-
Description
-
Follicle-Stimulating Hormone
-
Timepoint
-
At the beginning of the study (before the start of the intervention) and at the end of the study (8 weeks after the start of the intervention)
-
Method of measurement
-
Pars Azmoon Kit
20
-
Description
-
Free Androgen Index
-
Timepoint
-
At the beginning of the study (before the start of the intervention) and at the end of the study (8 weeks after the start of the intervention)
-
Method of measurement
-
Formula
21
-
Description
-
High-Sensitivity C-Reactive Protein
-
Timepoint
-
At the beginning of the study (before the start of the intervention) and at the end of the study (8 weeks after the start of the intervention)
-
Method of measurement
-
ELISA Kit
22
-
Description
-
Malondialdehyde
-
Timepoint
-
At the beginning of the study (before the start of the intervention) and at the end of the study (8 weeks after the start of the intervention)
-
Method of measurement
-
Spectrophotometry
23
-
Description
-
Total Antioxidant Capacity
-
Timepoint
-
At the beginning of the study (before the start of the intervention) and at the end of the study (8 weeks after the start of the intervention)
-
Method of measurement
-
Spectrophotometry
24
-
Description
-
Mental Health
-
Timepoint
-
At the beginning of the study (before the start of the intervention) and at the end of the study (8 weeks after the start of the intervention)
-
Method of measurement
-
The Depression, Anxiety and Stress Scale - 21 Items Questioner
25
-
Description
-
Quality of Sleep
-
Timepoint
-
At the beginning of the study (before the start of the intervention) and at the end of the study (8 weeks after the start of the intervention)
-
Method of measurement
-
Pittsburgh Sleep Quality Index
26
-
Description
-
Body Fat Percentage
-
Timepoint
-
At the beginning of the study (before the start of the intervention) and at the end of the study (8 weeks after the start of the intervention)
-
Method of measurement
-
Body Composition Analyzer
27
-
Description
-
Skeletal Muscle Mass
-
Timepoint
-
At the beginning of the study (before the start of the intervention) and at the end of the study (8 weeks after the start of the intervention)
-
Method of measurement
-
Body Composition Analyzer
Intervention groups
1
-
Description
-
Intervention group: Intaking120 grams per day of low-fat yogurt containing vitamin D (with a dose of 1000 IU or 25 micrograms) and vitamin E (with a dose of 50 IU or 34 mg) and two probiotic strains of lactobacillus (Lactobacillus acidophilus LA5) and bifidobacterium (Bifidobacterium animalis BB12) at least 10^6 cfu/g for 8 weeks
-
Category
-
Treatment - Other
2
-
Description
-
Control group: Intaking120 grams per day of conventional low-fat yogurt for 8 weeks as a placebo
-
Category
-
Treatment - Other
1
-
Sponsor
-
-
Grant name
-
-
Grant code / Reference number
-
-
Is the source of funding the same sponsor organization/entity?
-
Yes
-
Title of funding source
-
Shiraz University of Medical Sciences
-
Proportion provided by this source
-
100
-
Public or private sector
-
Public
-
Domestic or foreign origin
-
Domestic
-
Category of foreign source of funding
-
empty
-
Country of origin
-
-
Type of organization providing the funding
-
Academic
Sharing plan
-
Deidentified Individual Participant Data Set (IPD)
-
Undecided - It is not yet known if there will be a plan to make this available
-
Study Protocol
-
Undecided - It is not yet known if there will be a plan to make this available
-
Statistical Analysis Plan
-
Undecided - It is not yet known if there will be a plan to make this available
-
Informed Consent Form
-
Undecided - It is not yet known if there will be a plan to make this available
-
Clinical Study Report
-
Undecided - It is not yet known if there will be a plan to make this available
-
Analytic Code
-
Undecided - It is not yet known if there will be a plan to make this available
-
Data Dictionary
-
Undecided - It is not yet known if there will be a plan to make this available